Immune suppressor cells identified for advanced prostate cancer

December 21, 2015, University of Texas M. D. Anderson Cancer Center
Micrograph showing prostatic acinar adenocarcinoma (the most common form of prostate cancer) Credit: Wikipedia

Immune suppressor cells called MDSCs (myeloid-derived suppressor cells) may be important in developing treatments for advanced prostate cancer, according to a study at The University of Texas MD Anderson Cancer Center.

MDSCs are immune cells that "expand" when faced with , inflammation or infections, giving them the unique ability to suppress the body's T-cell response to disease.

"The microenvironment is made up of a mixture of fibroblasts, infiltrating immune cells and other cells, proteins and signaling molecules," said Y. Alan Wang, Ph.D., associate professor of Cancer Biology. "MDSCs are infiltrating that promote tumors through their striking lack of immunological response."

Wang and fellow scientists Ronald A. DePinho, M.D., professor of Cancer Biology, and president of MD Anderson, Xin Lu, Ph.D., instructor, and Guocan Wang, Ph.D., postdoctoral fellow, both of Cancer Biology were co-authors on a paper about the study's finding, which was published in the Dec. 20, 2015 online issue of Cancer Discovery.

Many previous studies have demonstrated a direct tie between MDSC and tumors, yet understanding of MDSC's role in tumor progress, particularly in , has remained largely speculative.

Using a novel prostate cancer mouse model and patient tumor samples, Wang's and DePinho's team showed that depletion of MDSCs suppresses tumor progression. In addition, they also revealed that a cell signaling pathway called Hippo-Yap1 regulated the protein Cxcl5 which was identified as a cancer-secreted chemokine that attracted or "recruited" MDSCs which expressed another protein, Cxcr2. The team was able to show that by blocking the Cxcr2 proteins with small molecule inhibitors, tumor progress was impeded. They also demonstrated that silencing of Yap1 expression in established tumors led to a reduction in MDSC infiltration and inhibition of tumor growth.

"Pharmacologic elimination of MDSCs or blockage of the Cxcl5-Cxcr2 signaling pathway resulted in robust anti-tumor response in vivo and prolonged survival," said DePinho. "The targeting of either MDSC recruitment or infiltrated MDSCs may represent a valid therapeutic opportunity in treating advanced prostate cancer."

Wang believes that further studies are needed, which may include combining MDSC inactivation with immunotherapy, including immune checkpoint inhibitors such as anti-CTLA4, anti PD1 and anti-PD-L1 antibodies.

Explore further: Scientists discover potential new target for cancer immunotherapy

Related Stories

Scientists discover potential new target for cancer immunotherapy

May 25, 2014
Scientists have found a way to target elusive cells that suppress immune response, depleting them with peptides that spare other important cells and shrink tumors in preclinical experiments, according to a paper published ...

Research findings reveal that tumors promote myeloid-derived suppressor cell accumulation through IRF-8 loss

September 17, 2013
(Medical Xpress)—Researchers at Roswell Park Cancer Institute (RPCI) have uncovered a new pathway by which cancer cells, such as in breast cancer, stimulate the expansion of myeloid-derived suppressor cells (MDSCs), a blood ...

Study finds potential key to immune suppression in cancer

January 19, 2012
In a study investigating immune response in cancer, researchers from Moffitt Cancer Center in Tampa, Fla., and the University of South Florida have found that interaction between the immune system's antigen-specific CD4 T ...

Study finds key link responsible for colon cancer initiation and metastasis

November 11, 2013
Chronic inflammation has long been known as a key risk factor for cancer—-particularly colon cancer—-but the exact mechanisms of how inflammation heightens the immune response, and ultimately influences the initiation ...

Researchers say silencing of retinoblastoma gene regulates differentiation of myeloid cells

February 19, 2013
Researchers at the Moffitt Cancer Center have found a potential mechanism by which immune suppressive myeloid-derived suppressor cells can prevent immune response from developing in cancer. This mechanism includes silencing ...

Blood vessel cells help tumours evade the immune system

August 24, 2015
A study by researchers at Sweden's Karolinska Institutet is the first to suggest that cells in the tumour blood vessels contribute to a local environment that protects the cancer cells from tumour-killing immune cells. The ...

Recommended for you

Daily low-dose aspirin may be weapon against ovarian cancer

July 20, 2018
(HealthDay)— One low-dose aspirin a day could help women avoid ovarian cancer or boost their survival should it develop, two new studies suggest.

Discovery of kidney cancer driver could lead to new treatment strategy

July 19, 2018
University of North Carolina Lineberger Comprehensive Cancer Center scientists have uncovered a potential therapeutic target for kidney cancers that have a common genetic change. Scientists have known this genetic change ...

Sunscreen reduces melanoma risk by 40 per cent in young people

July 19, 2018
A world-first study led by University of Sydney has found that Australians aged 18-40 years who were regular users of sunscreen in childhood reduced their risk of developing melanoma by 40 percent, compared to those who rarely ...

Analysis of prostate tumors reveals clues to cancer's aggressiveness

July 19, 2018
Using genetic sequencing, scientists have revealed the complete DNA makeup of more than 100 aggressive prostate tumors, pinpointing important genetic errors these deadly tumors have in common. The study lays the foundation ...

Complementary medicine for cancer can decrease survival

July 19, 2018
People who received complementary therapy for curable cancers were more likely to refuse at least one component of their conventional cancer treatment, and were more likely to die as a result, according to researchers from ...

Overcoming resistance to a standard chemotherapy drug

July 19, 2018
Despite being studied for decades, the chemotherapy drug cisplatin is revealing new aspects of how it works. Researchers at Winship Cancer Institute of Emory University have identified an enzyme responsible for making tumors ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.